The Product — What It Is
The launched product is a generic equivalent of Advair Diskus, a dry powder inhaler containing fluticasone propionate and salmeterol inhalation powder. It is indicated for the long-term treatment of asthma in patients aged four years and older and for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease. The product is being introduced in 100/50 mcg and 250/50 mcg strengths.
This delivery mechanism requires precision manufacturing of complex generic formulations, representing a shift toward higher-value respiratory therapies in the United States.
Commercial Opportunity
- Addressable US market for generic Advair Diskus is estimated at approximately $908 million according to IQVIA data
- Entry into a specialized low-competition segment involving complex dry powder inhaler technology
- Diversifies the US revenue stream beyond traditional solid oral dosage forms
- Leverages the established distribution network of Lannett Company LLC in the North American market
- Strengthens competitive positioning against other major generic players like Cipla and Hikma
Strategic Fit
This launch marks a significant milestone as the first commercialized product from the company's inhalation pipeline in the US. It validates the strategic acquisition of Lannett Company LLC, which was completed in June 2026 to enhance the group's domestic manufacturing footprint and complex generic capabilities. By successfully bringing a respiratory product to market, the company demonstrates its ability to navigate the stringent regulatory hurdles associated with inhaled drug-device combinations.
This aligns with a broader focus on expanding the portfolio into differentiated and complex therapy areas.
Business Overview
Aurobindo Pharma is an integrated global pharmaceutical leader headquartered in Hyderabad, India, with operations spanning over 150 countries. The company operates more than 30 manufacturing and packaging facilities globally, sanctioned by top-tier regulatory bodies including the USFDA and UK MHRA. Its portfolio covers seven major therapeutic areas, including CNS, anti-retrovirals, and antibiotics.
The company maintains a robust R&D foundation, with annual expenditure reaching approximately 1,622 crore to support its pipeline of over 800 Abbreviated New Drug Applications filed to date.
